Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

BACKGROUND: Afatinib has shown favorable response rates (RRs) and longer progression free survival (PFS) in lung cancer patients harboring EGFR mutations compared with standard platinum-based chemotherapy. However, serious adverse drug reactions (ADRs) limit the clinical application of afatinib. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Chieh, Tsai, Ming-Ju, Lee, Mei-Hsuan, Kuo, Chia-Yu, Shen, Mei-Chiou, Tsai, Ying-Ming, Chen, Huang-Chi, Hung, Jen-Yu, Huang, Ming-Shyan, Chong, Inn-Wen, Yang, Chih-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091516/
https://www.ncbi.nlm.nih.gov/pubmed/33941115
http://dx.doi.org/10.1186/s12885-021-08235-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091516/
https://www.ncbi.nlm.nih.gov/pubmed/33941115
http://dx.doi.org/10.1186/s12885-021-08235-3

Ejemplares similares